Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Connect Biopharma, for a wide-ranging conversation on the future of asthma and COPD treatment. With over 30 years in pharmaceutical R&D and nine FDA-approved drugs to his name, Barry shares a rare insider perspective on building and scaling biotech companies—from pioneering HIV therapies that reshaped the AIDS epidemic to leading next-generation biologics targeting acute asthma exacerbations. He unpacks Connect’s differentiated IL-4 receptor biology, the untapped opportunity in acute care settings, and why innovation has lagged for decades in treating exacerbations despite millions of ER visits annually. The conversation also explores the realities of running a publicly traded biotech in volatile markets, the evolving role of China in global drug discovery, and how leaders navigate geopolitical complexity while advancing science. As Connect approaches key clinical catalysts, this episode offers a compelling look at where biotech innovation, capital, and global strategy intersect. Biography: Dr. Barry Quart is the CEO of Connect Biopharma, (Nasdaq: CNTB), a clinical-stage company developing therapies for acute exacerbations of inflammatory diseases, such as asthma and COPD. Barry is currently leading the company’s development of rademikibart, a best-in-class antibody that targets interleukin-4 receptor alpha (IL-4Rα) and reduces severe flare-ups called “exacerbations” that can occur with asthma and COPD and can lead to hospitalization and even death. Connect is the first company to enter this space addressing acute exacerbations of inflammatory diseases. Dr. Quart is a recognized industry leader with over 30 years of leadership experience and nine FDA-approved drugs under his belt. Barry brings deep expertise in drug development, biotech strategy, and bringing breakthrough therapies to the market. He holds a PharmD from the University of California, San Francisco.

You can listen to Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership online on Radio and Podcast. Open the player on this page to stream the available audio.

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership is an episode from Biotech 2050 Podcast by Biotech2050 Podcast.

This episode is 00:23:07 long.

This episode was published on Apr 16, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Biotech 2050 Podcast when more episodes are available from the podcast feed.